2016
Change in a 17-gene genomic prostate score over time in men with low- and intermediate-risk prostate cancer managed with active surveillance.
Leapman M, Cowan J, Nguyen H, Cooperberg M, Carroll P. Change in a 17-gene genomic prostate score over time in men with low- and intermediate-risk prostate cancer managed with active surveillance. Journal Of Clinical Oncology 2016, 34: 124-124. DOI: 10.1200/jco.2016.34.2_suppl.124.Peer-Reviewed Original ResearchGenomic Prostate ScoreAdverse pathological findingsActive surveillanceProstate cancerRadical prostatectomyPathological findingsFavorable-risk prostate cancerIntermediate-risk prostate cancerIntermediate clinical riskNCCN risk classificationSerial prostate biopsyRisk prostate cancerSubsequent clinical outcomesTime of surgeryRT-PCR assaysPT3a diseaseDefinitive therapyIntermediate riskOncologic outcomesClinical outcomesAdverse pathologySerial biopsiesProstate biopsyMedian changeSerial changes
2015
Association between a 17-gene genomic prostate score and multiparametric prostate MRI in men with low- and intermediate-risk prostate cancer (PCa).
Leapman M, Westphalen A, Ameli N, Lawrence H, Febbo P, Cooperberg M, Carroll P. Association between a 17-gene genomic prostate score and multiparametric prostate MRI in men with low- and intermediate-risk prostate cancer (PCa). Journal Of Clinical Oncology 2015, 33: 83-83. DOI: 10.1200/jco.2015.33.7_suppl.83.Peer-Reviewed Original ResearchGenomic Prostate ScoreIntermediate-risk prostate cancerLow-risk patientsRisk prostate cancerFavorable pathologyProstate cancerMean apparent diffusion coefficientRisk patientsApparent diffusion coefficientAdverse pathologyIntermediate-risk patientsSuspicious MRI findingsProstate MRISuspicion of malignancyMultiparametric prostate MRIFive-tier scaleRT-PCR assaysMRI findingsSingle institutionMulti-parametric prostate MRIProstate biopsyDominant lesionRisk groupsMR findingsMR score